Unfortunately, adoptive transfer of VEGFR-2 CAR-T cells in a clinical setting was devoid of great success in a phase 1 clinical trial NCT01218867 on patients with metastatic cancer. This evidence concerns the gene KDR and metastatic malignant neoplasm.